Erin Wilson
Stock Analyst at Morgan Stanley
(1.16)
# 3,358
Out of 4,479 analysts
15
Total ratings
46.15%
Success rate
0.75%
Average return
Main Sectors:
10 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPD Rapid7 | Maintains: Equal-Weight | $52 → $55 | $42.72 | +28.75% | 3 | Nov 7, 2023 | |
| ALGN Align Technology | Maintains: Outperform | n/a | $239.74 | - | 2 | Jul 29, 2021 | |
| CRL Charles River Laboratories International | Maintains: Neutral | n/a | $201.48 | - | 1 | Jul 20, 2021 | |
| IQV IQVIA Holdings | Maintains: Outperform | n/a | $207.47 | - | 1 | Jul 20, 2021 | |
| MEDP Medpace Holdings | Maintains: Outperform | n/a | $404.42 | - | 1 | Jul 20, 2021 | |
| ICLR ICON PLC | Maintains: Outperform | n/a | $318.30 | - | 2 | Jul 20, 2021 | |
| ELAN Elanco Animal Health | Upgrades: Outperform | n/a | $14.01 | - | 1 | Feb 26, 2021 | |
| FLGT Fulgent Genetics | Downgrades: Underperform | n/a | $19.98 | - | 1 | Jan 8, 2021 | |
| TMO Thermo Fisher | Initiates: Neutral | n/a | $533.93 | - | 1 | Jan 22, 2020 | |
| INCR InterCure | Maintains: Outperform | n/a | $2.05 | - | 2 | Nov 14, 2017 |
Rapid7
Nov 7, 2023
Maintains: Equal-Weight
Price Target: $52 → $55
Current: $42.72
Upside: +28.75%
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: n/a
Current: $239.74
Upside: -
Charles River Laboratories International
Jul 20, 2021
Maintains: Neutral
Price Target: n/a
Current: $201.48
Upside: -
IQVIA Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: n/a
Current: $207.47
Upside: -
Medpace Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: n/a
Current: $404.42
Upside: -
ICON PLC
Jul 20, 2021
Maintains: Outperform
Price Target: n/a
Current: $318.30
Upside: -
Elanco Animal Health
Feb 26, 2021
Upgrades: Outperform
Price Target: n/a
Current: $14.01
Upside: -
Fulgent Genetics
Jan 8, 2021
Downgrades: Underperform
Price Target: n/a
Current: $19.98
Upside: -
Thermo Fisher
Jan 22, 2020
Initiates: Neutral
Price Target: n/a
Current: $533.93
Upside: -
InterCure
Nov 14, 2017
Maintains: Outperform
Price Target: n/a
Current: $2.05
Upside: -